Literature DB >> 24934714

Bovine viral diarrhoea virus ('pestivirus') in Australia: to control or not to control?

S R Lanyon1, M P Reichel.   

Abstract

BACKGROUND: Acute infection with bovine viral diarrhoea virus (BVDV) usually causes only mild clinical disease in cattle, but infection of animals of breeding age can result in immune suppression (resulting in an increased incidence and severity of secondary disease) and decreased reproductive performance. If infection occurs during pregnancy, the virus may cross the placenta and either cause abortion, establish immunotolerance and persistent infection (PI) in the fetus or cause congenital deformities. These outcomes depend on the stage of pregnancy at the time of infection. INTERNATIONAL PERSPECTIVE: BVDV is recognised as a disease of significant financial impact in a number of countries. As a result, national and regional BVDV control programs are now in place in several regions around the world. In Europe, these programs largely rely on the identification and removal of the PI animals, whereas vaccination has tended to be the chosen method of control in the United States. BVD IN AUSTRALIA: BVDV is endemic in Australian cattle populations, with more than 80% of herds surveyed showing some level of exposure to the pathogen. The cost to the national industry is estimated to be AUD57.9 million annually. This review identifies and discusses the challenges to BVDV control in Australia, including farmer attitudes, herd size, sheep as a potential reservoir host and diagnostic capabilities. We conclude that systematic BVDV control in Australia is, or soon will be, an option; however, detailed cost-benefit analyses will need to be undertaken.
© 2014 Australian Veterinary Association.

Entities:  

Keywords:  Australia; bovine viral diarrhoea virus; disease eradication; pestiviruses

Mesh:

Year:  2014        PMID: 24934714     DOI: 10.1111/avj.12208

Source DB:  PubMed          Journal:  Aust Vet J        ISSN: 0005-0423            Impact factor:   1.281


  7 in total

1.  Seroprevalence and risk factors assessment of the three main infectious agents associated with abortion in dairy cattle in Isfahan province, Iran.

Authors:  Vahid Noaman; Abdol Reza Nabinejad
Journal:  Trop Anim Health Prod       Date:  2020-01-25       Impact factor: 1.559

2.  Modeling the potential risk factors of bovine viral diarrhea prevalence in Egypt using univariable and multivariable logistic regression analyses.

Authors:  Abdelfattah M Selim; Mahmoud M Elhaig; Sherif A Moawed; Ehab El-Nahas
Journal:  Vet World       Date:  2018-03-02

3.  Prevalence of The Main Infectious Causes of Abortion in Dairy Cattle in Algeria.

Authors:  Salima-Yamina Derdour; Fella Hafsi; Naouelle Azzag; Safia Tennah; Abdelouahab Laamari; Bernard China; Farida Ghalmi
Journal:  J Vet Res       Date:  2017-09-19       Impact factor: 1.744

Review 4.  Perspectives on Current Challenges and Opportunities for Bovine Viral Diarrhoea Virus Eradication in Australia and New Zealand.

Authors:  Michael P Reichel; Sasha R Lanyon; Fraser I Hill
Journal:  Pathogens       Date:  2018-01-22

5.  Dendritic Cell Targeting of Bovine Viral Diarrhea Virus E2 Protein Expressed by Lactobacillus casei Effectively Induces Antigen-Specific Immune Responses via Oral Vaccination.

Authors:  Yixin Wang; Baohua Feng; Chao Niu; Shuo Jia; Chao Sun; Zhuo Wang; Yanping Jiang; Wen Cui; Li Wang; Yigang Xu
Journal:  Viruses       Date:  2019-06-25       Impact factor: 5.048

6.  Seroprevalence of Seven Reproductive Diseases in Beef and Dairy Cows from Three Provinces in Indonesia.

Authors:  Didik Tulus Subekti; Mira Fatmawati; Arie Khoiriyah; Arum Pramesthi; Sulinawati Fong; Muhammad Ibrahim Desem; Zul Azmi; Eni Kusumaningtyas; Dwi Endrawati; Eko Setyo Purwanto
Journal:  Vet Med Int       Date:  2021-12-02

7.  Prevalence characteristic of BVDV in some large scale dairy farms in Western China.

Authors:  Kang Zhang; Jingyan Zhang; Zhengying Qiu; Kai Zhang; Fenfen Liang; Qiaoni Zhou; Lei Wang; Jianxi Li
Journal:  Front Vet Sci       Date:  2022-07-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.